Search Results
Sinusbradycardia mint lehetséges favipiravir-mellékhatás
Sinus bradycardia as a potential side effect of favipiravir treatment
Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021; 102: 501–508. 5 Cai Q, Yang M, Liu D, et al. Experimental
alternatives are urgently needed as a rising COVID-19 pandemic and possible effects on global health [ 2 ]. Many medications such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical trials in several countries to assess their
Vírusellenes terápiás lehetőségek COVID–19 fertőzés kezelésére
Antiviral therapies for COVID-19 infections
References 1 Furuta, Y., Komeno, T., & Nakamura, T. (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the
A COVID–19-hez kapcsolódó májenzim-emelkedés valószínűleg multifaktoriális eredetű
COVID–19-associated liver enzyme elevation is probably multifactorial
Lexicomp. Favipiravir (United States: Not commercially available; refer to ‘Prescribing and Access Restrictions’ field): drug information. Available from: https://www.uptodate.com/contents/favipiravir
Gyorsreagálás a pandémiára, ellátásbiztonság
Rapid response to pandemia, supply security
complete synthesis of favipiravir from 2-aminopyrazine. Chemical Papers, Vol. 73, pp. 1043–1051. 3 Kacskovics, I. (2021) Magyar fejlesztésű gyógyszer a COVID ellen
Az akadémiai-ipari együttműködések szerepe a gyógyszerfejlesztésben pandémia idején
Drug development collaborations between Academia and Industry in Pandemia
References 1 Furuta, Y., Komeno, T., & Nakamura, T. (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the
] 42 Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020 Apr 4. 10.1002/cpt.1844 . [Epub ahead of
Citokinellenes terápia az új típusú koronavírus okozta megbetegedés (COVID–19) kezelésében – tocilizumab elsőként való alkalmazása egy hazai infektológiai osztályon
(A COVID–19-pandémia orvosszakmai kérdései)
D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020 Mar 18. 10.1016/j.eng.2020.03.007 . [Epub ahead of print
Az anti-SARS-CoV-2-IgG-antitest-immunválaszok monitorozása magyarországi egészségügyi dolgozók két kohorszában fertőzést, illetve immunizálást követően
Monitoring of anti-SARS-CoV-2 IgG antibody immune responses in two cohorts of Hungarian healthcare workers following infection or immunization
]. 7 Szabó BG, Lénárt KSz, Petrik B, et al. Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective
lopinavir/ritonavir or favipiravir was administered for five days. Intravenous methylprednisolone (1 mg kg −1 day −1 ) was administered to all patients during desaturation. Complete blood samples (2 mL) were collected from all patients in
